Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||114.00 x 100|
|Ask||116.40 x 200|
|Day's Range||110.60 - 118.40|
|52 Week Range||31.38 - 118.40|
|PE Ratio (TTM)||-22.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.
When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.